hit counter
Atara Biotherapeutics, Inc. (ATRA) Stock News Sentiment & Price - Sentifly
ATRA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Atara Biotherapeutics, Inc. (ATRA)

USA
Biotechnology
NASDAQ
ATRA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ATRA Latest news
Business Wire
Neutral
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
2021-11-08 16:01

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will participate at three upcoming virtual conferences. Cowen 5th Annual IO Next Summit Fireside chat on Monday, November 15, 2021

Business Wire
Neutral
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-05 16:01

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 52,474 restricted stock units of Atara's common stock to 15 newly hired employees and stock options to purchase an aggregate of 5,618 shares of Atara's common stock to one such newly hired emp

Seeking Alpha
Neutral
Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2021 Results - Earnings Call Transcript
2021-11-04 15:13

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
How Much Upside is Left in Atara Biotherapeutics (ATRA)? Wall Street Analysts Think 48%
2021-11-04 12:13

The consensus price target hints at a 48.3% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research
Positive
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
2021-11-04 11:28

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 2.17% and 1.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Business Wire
Neutral
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
2021-11-04 09:30

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the upcoming first release of efficacy and safety results from its Phase 3 ALLELE study. The pivotal trial is investigating tabelecleucel (tab-cel®) for the treatment of Epstein-Barr virus-positive po

Business Wire
Neutral
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
2021-11-04 07:30

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2021, recent business highlights and key catalysts over the next several months. “Atara continues to make meaningful progress across our strategic priorities and

Business Wire
Neutral
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
2021-10-28 16:01

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on Thursday, November 4, 2021. Following the release, the Company will host a live conference call and webcast at 8:30

Business Wire
Neutral
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
2021-10-13 07:30

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new translational data based on magnetization transfer ratio (MTR) and updated Phase 1 open-label extension (OLE) clinical data in patients with progressive multiple sclerosis (MS) treated with ATA188

Business Wire
Neutral
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
2021-10-04 07:30

SOUTH SAN FRANCISCO, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive

Loading more news...